Literature DB >> 10460074

Dosing recommendations in liver disease.

C Bergquist, J Lindegård, T Salmonson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10460074     DOI： 10.1016/S0009-9236(99)90058-9

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

1.  Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.

Authors:  Willi Cawello; Andreas Fichtner; Hilmar Boekens; Marina Braun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-09-20       Impact factor: 2.441

2.  The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.

Authors:  Nenad Sarapa; Margaret R Britto; Michelle B Mainka; Kourosh Parivar
Journal:  Eur J Clin Pharmacol       Date:  2005-05-11       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.

Authors:  S G Simonson; P D Martin; P Mitchell; D W Schneck; K C Lasseter; M J Warwick
Journal:  Eur J Clin Pharmacol       Date:  2003-01-30       Impact factor: 2.953

Review 4.  Regulatory aspects of pharmacokinetic profiling in special populations: a European perspective.

Authors:  Monica Edholm; Eva Gil Berglund; Tomas Salmonson
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.